Novel engineered peptides of a phage lysin as effective antimicrobials against multidrug-resistant Acinetobacter baumannii

Antimicrobial Agents and Chemotherapy

Volumn 60, Issue 5, 2016, Pages 2971-2979

  Thandar, Mya ^a   Lood, Rolf ^a,b   Winer, Benjamin Y ^a,c   Deutsch, Douglas R ^a   Euler, Chad W ^a,d   Fischetti, Vincent A ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

^b LUND UNIVERSITY   (Sweden)

^c Lewis Thomas Laboratory   (United States)

^d CITY UNIVERSITY OF NEW YORK   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL ENZYME; LYSIN; P307 PROTEIN; PEPTIDE DERIVATIVE; POLYPEPTIDE ANTIBIOTIC AGENT; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; CEFTAZIDIME; LEVOFLOXACIN; PEPTIDE; POLYMYXIN B;

ACINETOBACTER BAUMANNII; AMINO ACID COMPOSITION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL COUNT; BACTERIAL LOAD; BACTERIAL OUTER MEMBRANE; BACTERIOPHAGE; BIOFILM; CARBOXY TERMINAL SEQUENCE; CELL MEMBRANE; COLONY FORMING UNIT; CONTROLLED STUDY; DISULFIDE BOND; ENDOTOXIN DETECTION; FEMALE; GROWTH CURVE; IN VITRO STUDY; LIMIT OF DETECTION; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR WEIGHT; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; OUTER MEMBRANE; PRIORITY JOURNAL; ANIMAL; DRUG EFFECTS; GENETICS; MICROBIAL SENSITIVITY TEST; PATHOGENICITY; PROTEIN SECONDARY STRUCTURE;

ACINETOBACTER BAUMANNII; ANIMALS; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; BIOFILMS; CEFTAZIDIME; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; LEVOFLOXACIN; MICE; MICROBIAL SENSITIVITY TESTS; PEPTIDES; POLYMYXIN B; PROTEIN STRUCTURE, SECONDARY;

EID: 84964910629     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02972-15     Document Type: Article

References (36)

1. Potron A, Poirel L, Nordmann P. 2015. Emerging broad-spectrum resistance in Pseudomonas aeruginosa and Acinetobacter baumannii: mechanisms and epidemiology. Int J Antimicrob Agents 45:568-585. http://dx.doi.org/10.1016/j.ijantimicag.2015.03.001.
2. Zheng W, Yuan S, Li L. 2013. Analysis of hospital departmental distribution and antibiotic susceptibility of Acinetobacter isolated from sputum samples. Am J Infect Control 41:e73-76. http://dx.doi.org/10.1016/j.ajic.2012.11.004.
3. Bonnin RA, Nordmann P, Poirel L. 2013. Screening and deciphering antibiotic resistance in Acinetobacter baumannii: a state of the art. Expert Rev Anti Infect Ther 11:571-583. http://dx.doi.org/10.1586/eri.13.38.
4. Poirel L, Bonnin RA, Nordmann P. 2011. Genetic basis of antibiotic resistance in pathogenic Acinetobacter species. IUBMB Life 63:1061-1067. http://dx.doi.org/10.1002/iub.532.
5. Gayoso CM, Mateos J, Méndez JA, Fernández-Puente P, Rumbo C, Tomás M, Martínez de Ilarduya O, Bou G. 2014. Molecular mechanisms involved in the response to desiccation stress and persistence in Acinetobacter baumannii. J Proteome Res 13:460-476. http://dx.doi.org/10.1021/pr400603f.
6. Fishbain J, Peleg AY. 2010. Treatment of Acinetobacter infections. Clin Infect Dis 51:79-84. http://dx.doi.org/10.1086/653120.
7. Kanazawa K, Sato Y, Ohki K, Okimura K, Uchida Y, Shindo M, Sakura N. 2009. Contribution of each amino acid residue in polymyxin B3 to antimicrobial and lipopolysaccharide binding activity. Chem Pharm Bull 57:240-244. http://dx.doi.org/10.1248/cpb.57.240.
8. Brogden KA. 2005. Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria? Nat Rev Microbiol 3:238-250. http://dx.doi.org/10.1038/nrmicro1098.
9. Boohaker RJ, Lee MW, Vishnubhotla P, Perez JM, Khaled AR. 2012. The use of therapeutic peptides to target and to kill cancer cells. Curr Med Chem 19:3794-3804. http://dx.doi.org/10.2174/092986712801661004.
10. Justo JA, Bosso JA. 2015. Adverse reactions associated with systemic polymyxin therapy. Pharmacotherapy:35:28-33. http://dx.doi.org/10.1002/phar.1493.
11. Ko KS, Suh JY, Kwon KT, Jung SI, Park KH, Kang CI, Chung DR, Peck KR, Song JH. 2007. High rates of resistance to colistin and polymyxin B in subgroups of Acinetobacter baumannii isolates from Korea. J Antimicrob Chemother 60:1163-1167. http://dx.doi.org/10.1093/jac/dkm305.
12. Yele AB, Thawal ND, Sahu PK, Chopade BA. 2012. Novel lytic bacteriophage AB7-IBB1 of Acinetobacter baumannii: isolation, characterization and its effect on biofilm. Arch Virol 157:1441-1450. http://dx.doi.org/10.1007/s00705-012-1320-0.
13. Popova AV, Zhilenkov EL, Myakinina VP, Krasilnikova VM, Volozhantsev NV. 2012. Isolation and characterization of wide host range lytic bacteriophage AP22 infecting Acinetobacter baumannii. FEMS Microbiol Lett 332:40-46. http://dx.doi.org/10.1111/j.1574-6968.2012.02573.x.
14. Jin J, Li ZJ, Wang SW, Wang SM, Huang DH, Li YH, Ma YY, Wang J, Liu F, Chen XD, Li GX, Wang XT, Wang ZQ, Zhao GQ. 2012. Isolation and characterization of ZZ1, a novel lytic phage that infects Acinetobacter baumannii clinical isolates. BMC Microbiol 12:156. http://dx.doi.org/10.1186/1471-2180-12-156.
15. Lai MJ, Lin NT, Hu A, Soo PC, Chen LK, Chen LH, Chang KC. 2011. Antibacterial activity of Acinetobacter baumannii phage φAB2 endolysin (LysAB2) against both Gram-positive and Gram-negative bacteria. Appl Microbiol Biotechnol 90:529-539. http://dx.doi.org/10.1007/s00253-011-3104-y.
16. Lim JA, Shin H, Kang DH, Ryu S. 2012. Characterization of endolysin from a Salmonella Typhimurium-infecting bacteriophage SPN1S. Res Microbiol 163:233-241. http://dx.doi.org/10.1016/j.resmic.2012.01.002.
17. Walmagh M, Boczkowska B, Grymonprez B, Briers Y, Drulis-Kawa Z, Lavigne R. 2013. Characterization of five novel endolysins from Gramnegative infecting bacteriophages. Appl Microbiol Biotechnol 97:4369-4375. http://dx.doi.org/10.1007/s00253-012-4294-7.
18. Lood R, Winer BY, Pelzek AJ, Diez-Martinez R, Thandar M, Euler CW, Schuch R, Fischetti VA. 2015. Novel phage lysin capable of killing the multidrug-resistant Gram-negative bacterium Acinetobacter baumannii in a mouse bacteremia model. Antimicrob Agents Chemother 59:1983-1991. http://dx.doi.org/10.1128/AAC.04641-14.
19. Fischetti VA. 2008. Bacteriophage lysins as effective antibacterials. Curr Opin Microbiol 11:393-400. http://dx.doi.org/10.1016/j.mib.2008.09.012.
20. Briers Y, Walmagh M, Van Puyenbroeck V, Cornelissen A, Cenens W, Aertsen A, Oliveira H, Azeredo J, Verween G, Pirnay JP, Miller S, Volckaert G, Lavigne R. 2014. Engineered endolysin-based "artilysins" to combat multidrug-resistant Gram-negative pathogens. mBio 5:e01379-14. http://dx.doi.org/10.1128/mBio.01379-14.
21. Lukacik P, Barnard TJ, Keller PW, Chaturvedi KS, Seddiki N, Fairman JW, Noinaj N, Kirby TL, Henderson JP, Steven AC, Hinnebusch BJ, Buchanan SK. 2012. Structural engineering of a phage lysin that targets Gram-negative pathogens. Proc Natl Acad Sci U S A 109:9857-9862. http://dx.doi.org/10.1073/pnas.1203472109.
22. Lukacik P, Barnard TJ, Buchanan SK. 2012. Using a bacteriocin structure to engineer a phage lysin that targets Yersinia pestis. Biochem Soc Trans 40:1503-1506. http://dx.doi.org/10.1042/BST20120209.
23. Wellings DA, Atherton E. 1997. Standard Fmoc protocols. Methods Enzymol 289:44-67. http://dx.doi.org/10.1016/S0076-6879(97)89043-X.
24. Knorr R, Trzeciak A, Bannwarth W, Gillessen D. 1989. New coupling reagents in peptide chemistry. Tetrahedron Lett 30:1927-1930. http://dx.doi.org/10.1016/S0040-4039(00)99616-3.
25. Clinical Laboratory and Standards Institute. 2012. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard-8th ed. CLSI document M07-A9, vol 32, no 2. Clinical and Laboratory Standards Institute, Wayne, PA.
26. Djurkovic S, Loeffler JM, Fischetti VA. 2005. Synergistic killing of Streptococcus pneumoniae with the bacteriophage lytic enzyme Cpl-1 and penicillin or gentamicin depends on the level of penicillin resistance. Antimicrob Agents Chemother 49:1225-1228. http://dx.doi.org/10.1128/AAC.49.3.1225-1228.2005.
27. Park CB, Kim HS, Kim SC. 1998. Mechanism of action of the antimicrobial peptide buforin II: buforin II kills microorganisms by penetrating the cell membrane and inhibiting cellular functions. Biochem Biophys Res Commun 244:253-257. http://dx.doi.org/10.1006/bbrc.1998.8159.
28. Chen HL, Su PY, Chang YS, Wu SY, Liao YD, Yu HM, Lauderdale TL, Chang K, Shih C. 2013. Identification of a novel antimicrobial peptide from human hepatitis B virus core protein arginine-rich domain (ARD). PLoS Pathog 9:e1003425. http://dx.doi.org/10.1371/journal.ppat.1003425.
29. Saugar JM, Alarcón T, López-Hernández S, López-Brea M, Andreu D, Rivas L. 2002. Activities of polymyxin B and cecropin A-melittin peptide CA(1-8)M(1-18) against a multiresistant strain of Acinetobacter baumannii. Antimicrob Agents Chemother 46:875-878. http://dx.doi.org/10.1128/AAC.46.3.875-878.2002.
30. Pastagia M, Euler C, Chahales P, Fuentes-Duculan J, Krueger JG, Fischetti VA. 2011. A novel chimeric lysin shows superiority to mupirocin for skin decolonization of methicillin-resistant and -sensitive Staphylococcus aureus strains. Antimicrob Agents Chemother 55:738-744. http://dx.doi.org/10.1128/AAC.00890-10.
31. Zhang Y. 2008. I-TASSER server for protein 3D structure prediction. BMC Bioinformatics 9:40. http://dx.doi.org/10.1186/1471-2105-9-40.
32. Roy A, Kucukural A, Zhang Y. 2010. I-TASSER: a unified platform for automated protein structure and function prediction. Nat Protoc 5:725-738. http://dx.doi.org/10.1038/nprot.2010.5.
33. Roy A, Yang J, Zhang Y. 2012. COFACTOR: an accurate comparative algorithm for structure-based protein function annotation. Nucleic Acids Res 40:W471-W477. http://dx.doi.org/10.1093/nar/gks372.
34. Perez F, Hujer AM, Hujer KM, Decker BK, Rather PN, Bonomo RA. 2007. Global challenge of multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 51:3471-3484. http://dx.doi.org/10.1128/AAC.01464-06.
35. Roca I, Espinal P, Vila-Farrés X, Vila J. 2012. The Acinetobacter baumannii oxymoron: commensal hospital dweller turned pan-drugresistant menace. Front Microbiol 3:148. http://dx.doi.org/10.3389/fmicb.2012.00148.
36. Dijkshoorn L, Nemec A, Seifert H. 2007. An increasing threat in hospitals: multidrug-resistant Acinetobacter baumannii. Nat Rev Microbiol 5:939-951. http://dx.doi.org/10.1038/nrmicro1789.